Journal of Surgical Research
Volume 155, Issue 1 , Pages 40-47 , July 2009

Pharmacological Synergism Between Cannabinoids and Paclitaxel in Gastric Cancer Cell Lines

Received 9 March 2008

References 

  1. Pertwee RG. Cannabinoid receptor ligands: Clinical and neuropharmacological considerations, relevant to future drug discovery and development. Exp Opin Invest Drugs. 2000;9:1
  2. Piomelli D, Giuffrida A, Calignano A, et al. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci. 2000;21:218
  3. Porter AC, Felder CC. The endocannabinoid nervous system: Unique opportunities for therapeutic intervention. Pharmacol Ther. 2001;90:45
  4. Devane WA, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946
  5. Mechoulam R, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50:83
  6. Matsuda LA, Lolait SJ, Brownstein M, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1999;346:561
  7. Wright K, et al. Differential expression of cannabinoid receptors in the human colon: Cannabinoids promote epithelial wound healing. Gastroenterology. 2005;129:437
  8. Ligresti A, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. 2003;125:677
  9. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61
  10. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5:400
  11. Steffens S, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature. 2005;434:782
  12. Guzman M. Cannabinoids: Potential anticancer agents. Nat Rev Cancer. 2003;3:745
  13. Galve-Roperh I. Antitumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med. 2000;6:313
  14. de Petrocellis L. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA. 1998;95:8375
  15. Melck D, de Petrocellis L, di Marzo V. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology. 2000;141:118
  16. Sarfaraz S, Afaq F, Adhami VM, et al. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 2005;65:1635
  17. Mimeault M, Pommery N, Wattez N, et al. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: Implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate. 2003;56:1
  18. Guzman M, Sanchez C, Galve-Roperh I. Cannabinoids and cell fate. Pharmacol Ther. 2002;5:175
  19. Llanos Casanova M, Blázquez C, Guzmán M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest. 2003;111:43
  20. Blázquez C, González-Feria L, Guzmán M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 2004;64:5617
  21. Portella G, Laezza C, Bifulco M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: Actions on signals involved in angiogenesis and metastasis. FASEB J. 2003;17:1771
  22. Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor α-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 2004;64:1943
  23. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer. 2003;11:137
  24. Hall W, Degenhardt L. Medical marijuana initiatives: Are they justified? How successful are they likely to be?. Cent Nerv Syst Drugs. 2003;17:689
  25. Pascual D, Goicoechea C, Martin MI. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain. 2005;118:23
  26. Chang YF, Li LL, Wu CW, et al. Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer. 1996;77:14
  27. Ajani JA, Fairweather J, Dumas P, et al. Phase II study of Taxol in patients with untreated metastatic gastric carcinoma. Cancer J Sci Am. 1998;4:269
  28. Yamada Y, Shirao K, Ohtsu A, et al. Phase II trial of paclitaxel by 3-h infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol. 2001;12:1133
  29. Garcia AA, Leichman CG, Lenz HJ, et al. Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach. Jpn J Clin Oncol. 2001;31:275
  30. Ohtsu A, Boku N, Tamura F, et al. An early Phase II study of a 3-h infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol. 1998;21:416
  31. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N. Engl. J. Med. 1995;332:1004
  32. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253
  33. Kapil N, Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene. 2003;22:9075
  34. Faried LS, Faried A, Kanuma T, et al. Inhibition of the mammalian target of rapamycin (mTor) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Eur J Cancer. 2006;42:934
  35. Faried A, Faried LS, Kimura H, et al. Differential sensitivity of paclitaxel-induced apoptosis in human esophageal squamous cell carcinoma cell lines. Cancer Chemother Pharmacol. 2006;57:301
  36. Jacobsson SO, Rongard E, Stridh M, et al. Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol. 2000;60:1807
  37. Holland ML, Panetta JA, Arnold JC. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem Pharmacol. 2006;71:1146
  38. Charles AG. Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother Pharmacol. 2001;47:444
  39. Brenneisen R, Egli A, Elsohly MA, et al. The effect of orally and rectally administered δ9-tetrahydrocannabinol on spasticity: A pilot study with two patients. Int J Clin Pharmacol Ther. 1996;34:446
  40. Consroe P, Kennedy K, Schram K. Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem Behav. 1991;40:517

PII: S0022-4804(08)00452-6

doi: 10.1016/j.jss.2008.06.045

Journal of Surgical Research
Volume 155, Issue 1 , Pages 40-47 , July 2009

Article Tools

* Image Usage & Resolution